Quick Answer
NORTHWEST BIOTHERAPEUTICS INC reported Cash and Equivalents of $2.17 million for fiscal year 2024.
NORTHWEST BIOTHERAPEUTICS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $2.17M | +2.3% |
| 2023 | $2.13M | -69.5% |
| 2022 | $6.96M | -54.1% |
| 2021 | $15.17M | +51.9% |
| 2020 | $9.98M | +2583.6% |
| 2019 | $372.0K | -98.3% |
| 2018 | $22.22M | +18894.9% |
| 2017 | $117.0K | -98.3% |
| 2016 | $6.87M | -68.5% |
| 2015 | $21.81M | +62.9% |
| 2014 | $13.39M | -27.6% |
| 2013 | $18.50M | +151.8% |
| 2012 | $7.35M | +30508.3% |
| 2011 | $24.0K | -84.3% |
| 2010 | $153.0K | +135.4% |
| 2009 | $65.0K | — |
| 1996 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.56M | +55.2% | +5.7% |
| June 30, 2025 | $4.32M | +49.8% | +55.3% |
| March 31, 2025 | $2.78M | +12.1% | +27.8% |
| December 31, 2024 | $2.17M | +2.3% | -26.0% |
| September 30, 2024 | $2.94M | -51.8% | +2.0% |
| June 30, 2024 | $2.88M | +102.3% | +16.3% |
| March 31, 2024 | $2.48M | -60.0% | +16.6% |
| December 31, 2023 | $2.13M | -69.5% | -65.1% |
- NORTHWEST BIOTHERAPEUTICS INC showed an increase of +2.3% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from NORTHWEST BIOTHERAPEUTICS INC’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: